KAITLYN GOVATOS: Open Payments
NPI 1780237966 · ARNOLD, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$652 in 25 payments from 10 companies in 2025. Trend: 2023 $347 · 2024 $215 · 2025 $652
Food & beverage: $652
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 8 | $179 |
| Novo Nordisk Inc | 7 | $167 |
| Medtronic, Inc. | 1 | $104 |
| Astellas Pharma US Inc | 2 | $48 |
| Boston Scientific Corporation | 1 | $45 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $36 |
| Optinose US, Inc. | 1 | $21 |
| Amgen Inc. | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Collegium Pharmaceutical, Inc. | 1 | $14 |
Products named: VRAYLAR, SYMPLICITY G3, Ozempic, Rybelsus, Veozah, WaveWriter Alpha Prime 16, XIFAXAN, Wegovy.
Industry payments across MD — which companies pay providers there.
